<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857270</url>
  </required_header>
  <id_info>
    <org_study_id>16419</org_study_id>
    <secondary_id>I8S-MC-JUAB</secondary_id>
    <secondary_id>2016-001907-21</secondary_id>
    <nct_id>NCT02857270</nct_id>
  </id_info>
  <brief_title>A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer</brief_title>
  <official_title>A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of an extracellular signal regulated
      kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in
      participants with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2016</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (21 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of LY3214996 Administered as Monotherapy and when Administered in Combination with Nab-Paclitaxel Plus Gemcitabine, Abemaciclib and Encorafenib Plus Cetuximab</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (up to 28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Gemcitabine when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Nab-Paclitaxel when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Abemaciclib and its Metabolites when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Encorafenib when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Cetuximab when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Midazolam and its 1'-Hydroxymidazolam Metabolite when Administered Alone and in Combination with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 16 (21 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants With a Complete (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Estimated up to 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response (TTR)</measure>
    <time_frame>Baseline to Date of CR or PR (Estimated up to 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Progressive Disease or Death of Any Cause (Estimated up to 12 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Dose Expansion Arms Only)</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Estimated up to 2 Years)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">245</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Metastatic Non-small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>LY3214996 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally once a day (or twice a day) for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 + Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Preliminary Drug-Drug Interactions [DDI])
LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally (once a day) during each 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 + Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 + Nab-Paclitaxel + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 + Encorafenib + Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japan Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japan Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally and abemaciclib given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japan Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally, nab-paclitaxel given IV and gemcitabine IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3214996</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Japan Part 1</arm_group_label>
    <arm_group_label>Japan Part 2</arm_group_label>
    <arm_group_label>Japan Part 3</arm_group_label>
    <arm_group_label>LY3214996 + Abemaciclib</arm_group_label>
    <arm_group_label>LY3214996 + Encorafenib + Cetuximab</arm_group_label>
    <arm_group_label>LY3214996 + Midazolam</arm_group_label>
    <arm_group_label>LY3214996 + Nab-Paclitaxel + Gemcitabine</arm_group_label>
    <arm_group_label>LY3214996 Dose Escalation</arm_group_label>
    <arm_group_label>LY3214996 Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3214996 + Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Japan Part 2</arm_group_label>
    <arm_group_label>LY3214996 + Abemaciclib</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Japan Part 3</arm_group_label>
    <arm_group_label>LY3214996 + Nab-Paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Japan Part 3</arm_group_label>
    <arm_group_label>LY3214996 + Nab-Paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3214996 + Encorafenib + Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3214996 + Encorafenib + Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have advanced or metastatic cancer (solid tumors) and be an appropriate candidate for
             experimental therapy.

               -  Part B (No Longer Enrolling Participants): Have advanced or metastatic cancer
                  with an activating mitogen-activated protein kinase pathway alteration, BRAF
                  mutant metastatic melanoma refractory to or relapsed after treatment with RAF
                  and/or MEK inhibitors, metastatic melanoma with a NRAS mutation, or BRAF mutant
                  NSCLC.

               -  Part C: Advanced, unresectable cancer (dose escalation) and advanced,
                  unresectable, or metastatic non-small cell lung cancer with a BRAF or RAS
                  mutation, or NRAS mutant melanoma (dose expansion).

               -  Part D (No Longer Enrolling Participants): Have metastatic pancreatic ductal
                  adenocarcinoma (dose escalation and dose expansion).

               -  Part E: Metastatic BRAF V600E colorectal cancer.

          -  Have discontinued previous treatments for cancer and have resolution, except where
             otherwise stated in the inclusion criteria, of all clinically significant toxic
             effects of prior chemotherapy, surgery, or radiotherapy to Grade ≤1 by National Cancer
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.

          -  Have adequate organ function.

          -  Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

        Exclusion Criteria:

          -  Have serious preexisting medical conditions.

          -  Have a known human immunodeficiency virus (HIV) infection or known
             activated/reactivated hepatitis A, B, or C.

          -  Have symptomatic central nervous system malignancy or metastasis.

          -  Have current hematologic malignancies, acute or chronic leukemia.

          -  Have a second primary malignancy that in the judgment of the investigator or Lilly may
             affect the interpretation of results.

          -  Have prior malignancies. Participants with carcinoma in situ of any origin and
             participants with prior malignancies who are in remission and whose likelihood of
             recurrence is very low, as judged by the Lilly clinical research physician, are
             eligible for this study.

          -  Have a mean QT interval corrected for heart rate (QTc) of ≥470 milliseconds on
             screening electrocardiogram (ECG) as calculated using the Bazett's formula at several
             consecutive days of assessment.

          -  Have participated, within the last 28 days in a clinical trial involving an
             investigational product or are currently enrolled in a clinical trial involving an
             investigational product or any other type of medical research judged not to be
             scientifically or medically compatible with this study.

          -  Have previously completed or withdrawn from this study or any other study
             investigating an ERK1/2 inhibitor.

          -  If female, is pregnant, breastfeeding, or planning to become pregnant.

          -  Have history or findings of central or branch retinal artery or venous occlusion with
             significant vision loss or other retinal diseases that cause current visual impairment
             or would likely cause visual impairment over the time period of the study.

          -  Currently using concomitant medications that are strong inhibitors or inducers of
             CYP3A4.

          -  Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the
             judgment of the investigator, would preclude participation in this study, including
             interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy.

          -  Part C4 NRAS Melanoma: have previously completed or withdrawn from a study
             investigating a MEK inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>202-444-2223</phone>
    </contact>
    <investigator>
      <last_name>Stephen V Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9413779993</phone>
    </contact>
    <investigator>
      <last_name>Manish Rajni Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-643-3614</phone>
    </contact>
    <investigator>
      <last_name>Ryan Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>603-650-8162</phone>
    </contact>
    <investigator>
      <last_name>Konstantin Dragnev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>212-639-2000</phone>
    </contact>
    <investigator>
      <last_name>Michael Offin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-864-7859</phone>
    </contact>
    <investigator>
      <last_name>Timothy F Burns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>SMO Sarah Cannon Research Inst.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>6153297274</phone>
    </contact>
    <investigator>
      <last_name>Johanna Chock Bendell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-745-6601</phone>
    </contact>
    <investigator>
      <last_name>Shubham Pant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61293555655</phone>
    </contact>
    <investigator>
      <last_name>Anthony Joshua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61893463823</phone>
    </contact>
    <investigator>
      <last_name>Michael Millward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33142114385</phone>
    </contact>
    <investigator>
      <last_name>Antoine Hollebecque</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-Gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120360605</phone>
    </contact>
    <investigator>
      <last_name>Tomoya Yokota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120360605</phone>
    </contact>
    <investigator>
      <last_name>Toshio Shimizu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/solid-tumor/JUAB#?postal=</url>
    <description>Click here for more information about this study: A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer</description>
  </link>
  <verification_date>July 1, 2020</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MAPK</keyword>
  <keyword>RAS</keyword>
  <keyword>BRAF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

